Skip to main content
OpenTrials
Completed

NCT Number: NCT03591367

The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation

We try to assess the potential role of telomerase reverse transcriptase and MicroRNA (miR-155) in diagnosis of non-muscle-invasive bladder cancer and their correlation with stage and grade of the tumor.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bladder Cancer Bladder Disease Bladder Neoplasm Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Male Urogenital Diseases Micro-RNA Neoplasms Neoplasms by Site Urinary Bladder Diseases Urinary Bladder Neoplasms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Urology and Nephrology Center

Al Mansurah, Aldakahlia, 35516, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women 18 years or older.
  • Patient with hematuria suspected to be of bladder origin clinically.
  • Willing to be participate in the study.

Exclusion criteria

  • Patient having another malignancy.
  • Hematuria of other causes as trauma and stones

Treatment and study plan

MicroRNAs-155

Diagnostic Test

Quantitative analysis of cell-free miR-155 using RT-qPCR.

Other names: (miRNAs-155)

Human telomerase reverse transcriptase

Diagnostic Test

Analysis TERT by TERT messenger RNA (mRNA)expression by reverse transcription-quantitative polymerase chain reaction.

Other names: (hTERT)

Primary outcomes

  1. sensitivity, specificity and positive and negative predictive values of combined MicroRNA-155 And Telomerase Reverse Transcriptase In diagnosis Of Non-Muscle Invasive Bladder Cancer

    Time frame: 1 year

    compared by standard final pathological specimen

Secondary outcomes

  1. correlation between serum Vit D and Non-Muscle Invasive Bladder Cancer

    Time frame: 1 year

    measured serum Vit D in ng/mL.

Sponsors and collaborators

Lead sponsor

Mansoura University

Other

Registry information

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jul 19, 2018
Registry last updated
Nov 4, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.